# Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

> **NCT05243823** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 500000 (actual)

## Conditions studied

- Postmenopausal Vaginal Atrophy

## Interventions

- **DRUG:** Vagifem®
- **DRUG:** Non-Vagifem® LDVE, Estradiol

## Key facts

- **NCT ID:** NCT05243823
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-15
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 500000 (ACTUAL)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243823, "Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05243823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*